NR1H4 and metabolic dysfunction-associated steatohepatitis: FXR is an attractive target for the development of antiviral molecules as some FXR ligands have already been approved for patients with primary biliary cholangitis or are currently in clinical evaluation in patients with NASH.36 Moreover, one FXR ligand is currently in a phase II clinical trial in patients with chronic HBV infection (Clinical Trial identifiers NCT04365933 and NCT04465916).